Cargando…

Coagulopathy and Extremely Elevated PT/INR after Dabigatran Etexilate Use in a Patient with End-Stage Renal Disease

Introduction. Dabigatran is an oral direct thrombin inhibitor which has been approved for prophylaxis of stroke in patients with atrial fibrillation. The use of dabigatran etexilate increased rapidly due to many benefits. However, questions have been raised constantly regarding the safety of dabigat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Joonseok, Yadava, Mrinal, An, In Chul, Sayeed, Abrar, Laird-Fick, Heather S., Gourineni, Venu, Abela, George S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3789314/ https://www.ncbi.nlm.nih.gov/pubmed/24151507 http://dx.doi.org/10.1155/2013/131395

Ejemplares similares

Pericarditis in Takotsubo Cardiomyopathy: A Case Report and Review of the Literature
por: Kim, Joonseok, et al.
Publicado: (2013)

The Discovery of Dabigatran Etexilate
por: van Ryn, Joanne, et al.
Publicado: (2013)

Extremely Elevated International Normalized Ratio in a Patient with Dabigatran Etexilate Use
por: Memon, Waqas, et al.
Publicado: (2019)

Dabigatran etexilate tetrahydrate
por: Liu, Hong-Qiang, et al.
Publicado: (2012)

New options with dabigatran etexilate in anticoagulant therapy
por: Maegdefessel, Lars, et al.
Publicado: (2010)

Dabigatran-etexilate: Lack of efficacy: case report
Publicado: (2021)

Recovery of Visual Function after Administration of Dabigatran Etexilate
por: Schönfeld, Carl-Ludwig, et al.
Publicado: (2014)

Dabigatran etexilate: Cholestatic liver injury: case report
Publicado: (2021)

Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation
por: Huber, K, et al.
Publicado: (2013)

The effects of dabigatran etexilate on fracture healing in rats: An experimental study
por: Kerimoglu, Servet, et al.
Publicado: (2015)

Hemopericardium and Cardiac Tamponade in a Patient Treated with Dabigatran Etexilate
por: Kızılırmak, Filiz, et al.
Publicado: (2016)

Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile
por: Clemens, Andreas, et al.
Publicado: (2012)

Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate
por: Bellamy, L, et al.
Publicado: (2009)

The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients
por: Ellis, Christopher R, et al.
Publicado: (2013)

The modification of the thrombin generation test for the clinical assessment of dabigatran etexilate efficiency
por: Gribkova, Irina V., et al.
Publicado: (2016)

Role of POC INR in the early stage of diagnosis of coagulopathy
por: Raimann, Florian J., et al.
Publicado: (2021)

Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers
por: Härtter, Sebastian, et al.
Publicado: (2012)

What neurosurgeons need to know about dabigatran etexilate (pradax(®)/pradaxa(®)/prazaxa(®))
por: Dwyer, Christopher Michael, et al.
Publicado: (2015)

The effect of oral dabigatran etexilate on bone density, strength, and microstructure in healthy mice
por: Brent, Mikkel Bo, et al.
Publicado: (2017)

In Vitro Selection of Specific DNA Aptamers Against the Anti-Coagulant Dabigatran Etexilate
por: Aljohani, Maher M., et al.
Publicado: (2018)

Apixaban/dabigatran etexilate/enoxaparin sodium: Various toxicities: 8 case reports
Publicado: (2022)

Rhabdomyolysis happened after the start of dabigatran etexilate treatment: A case report
por: Zheng, Tingting, et al.
Publicado: (2022)

Estimation Based on Emission Wavelength of Dabigatran Etexilate Mesylate in Bulk and Capsule Dosage Form
por: Anumolu, P. D., et al.
Publicado: (2016)

Exposure Response Supports Therapeutic Drug Monitoring for Dabigatran Etexilate in Patients with Atrial Fibrillation
por: Simpson, Bryan H., et al.
Publicado: (2019)

FDA committee unanimously recommends approval of dabigatran etexilate for stroke prevention in atrial fibrillation
por: J, Aalbers, et al.
Publicado: (2010)

Predicted effect of ticagrelor on the pharmacokinetics of dabigatran etexilate using physiologically based pharmacokinetic modeling
por: Wang, Nan, et al.
Publicado: (2020)

Population pharmacokinetic analysis for dabigatran etexilate in Chinese patients with non-valvular atrial fibrillation
por: Liu, Ya-ou, et al.
Publicado: (2022)

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation
por: Kansal, Anuraag R, et al.
Publicado: (2012)

Oral Thromboprophylaxis Following Total Hip or Knee Replacement: Review and Multicentre Experience with Dabigatran Etexilate
por: Kendoff, D, et al.
Publicado: (2011)

Adverse events in patients initiated on dabigatran etexilate therapy in a pharmacist-managed anticoagulation clinic
por: Donaldson, Mark, et al.
Publicado: (2013)

Impact of Pharmacists’ audit on improving the quality of prescription of dabigatran etexilate methanesulfonate: a retrospective study
por: Shimizu, Teppei, et al.
Publicado: (2017)

Myotonic dystrophy type 1 and pulmonary embolism: successful thrombus resolution with dabigatran etexilate therapy
por: GALLINORO, EMANUELE, et al.
Publicado: (2018)

Choice of Renal Function Estimator Influences Adverse Outcomes with Dabigatran Etexilate in Patients with Atrial Fibrillation
por: Simpson, Bryan H., et al.
Publicado: (2018)

Pharmacokinetics and Safety of Dabigatran Etexilate after Single and Multiple Oral Doses in Healthy Chinese Subjects
por: Duan, Jingli, et al.
Publicado: (2020)

Physiologically‐based pharmacokinetics modeling to investigate formulation factors influencing the generic substitution of dabigatran etexilate
por: Farhan, Nashid, et al.
Publicado: (2021)

Design and rationale for the DIVERSITY study: An open‐label, randomized study of dabigatran etexilate for pediatric venous thromboembolism
por: Albisetti, Manuela, et al.
Publicado: (2018)

Pharmacokinetic modeling and simulation support for age‐ and weight‐adjusted dosing of dabigatran etexilate in children with venous thromboembolism
por: Röshammar, Daniel, et al.
Publicado: (2021)

Dabigatran etexilate for thromboprophylaxis in over 5000 hip or knee replacement patients in a real-world clinical setting
por: Rosencher, Nadia, et al.
Publicado: (2016)

Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolism
por: Albisetti, Manuela, et al.
Publicado: (2017)

Anticoagulation efficacy of dabigatran etexilate for left atrial appendage thrombus in patients with atrial fibrillation by transthoracic and transesophageal echocardiography
por: Xing, Xiao Fei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_oaq8rk4mt26lvidn8lihf05cdo